Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With DLBCL

University Hospital, Saarland79 enrolled

Overview

Multi-center retrospective analysis of patients with DLBCL aged ≥80 years old treated with R-CHOP-14 compared to other regimens. Patient data including baseline characteristics, histology, dose intensity and treatment outcomes will be extracted from hospital medical electronic records. Relative dose intensity (RDI) will be calculated as the percentage of the dose intensity achieved divided by the intended dose intensity. Primary endpoints are overall (OS), progression-free (PFS) and event-free survival (EFS), defined as time from diagnosis to death, death or progression/relapse, progression/relapse or treatment discontinuation.

Study Type

OBSERVATIONAL

Enrollment

Conditions

DLBCL Old Age; Debility

Eligibility

Sex: ALLMin age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * histologically proven, untreated diffus large B-cell lymphoma (DLBCL) * diagnosis between 2005 - 2019 * age ≥80 at diagnosis Exclusion Criteria: \- diagnosis revision at a later timepoint

Locations (1)

Saarland University Medical Center

Homburg, Saarland, Germany

Outcomes

Primary Outcomes

Overall survival (OS) death or progression/relapse, progression/relapse or treatment discontinuation.

time from diagnosis to death

Time frame: through study completion, an average of 2 years

Progression-free survival (PFS)

time from diagnosis to death or progression/relapse

Time frame: through study completion, an average of 2 years

Event-free survival (EFS)

defined as time from diagnosis to death or progression/relapse or treatment discontinuation.

Time frame: through study completion, an average of 2 years

Secondary Outcomes

Relative Dose intensity

Percentage of the dose intensity achieved divided by the intended dose intensity

Time frame: within the treatment period, up to 36 weeks